Patients with myeloproliferative disorders that have a decrease in 12-LOX expression have an increase in bleeding and a reduction in thrombotic complications compared to myeloproliferative patients with normal 12-LOX levels (Schafer, 1982; Okuma et al., 1989; Matsuda et al., 1993). This evidence concerns the gene ALOX15 and myeloproliferative disorder.